Blood test may spot pancreatic cancer without needle biopsy
NCT ID NCT02072616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a blood test that detects circulating tumor cells (CTCs) could diagnose pancreatic cancer. Researchers planned to compare the blood test results with standard tissue biopsies in 101 people with pancreatic tumors. The trial was terminated early, so the full potential of this approach remains unclear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could offer a less invasive way to diagnose pancreatic cancer, potentially reducing the need for risky biopsies.
- What could go wrong
- The trial was terminated early, so results are limited. The approach is still experimental and not yet proven to replace standard diagnostic methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CA 19.9 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UH Rouen
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors